Personalized cancer vaccines cross the Phase III "life and death threshold"! Moderna (MRNA.US) shares soar 177% in one day, mRNA chain sees a "second value awakening"

According to Zhitong Finance APP, Moderna (MRNA.US), a leading player in the mRNA vaccine field, saw its market capitalization double on Wednesday with a record-breaking surge in share price. By the close of U.S. markets on Wednesday, its stock had soared by 177%, driving up the share prices of competitors in the biomedical and healthcare sectors. The company, together with U.S. pharmaceutical giant Merck (MRK.US), has made major progress in a late-stage (phase III) clinical trial of a cancer vaccine based on messenger RNA technology (mRNA), achieving the primary endpoint in melanoma patients.

Reflecting the robust consensus on the growth potential of this biomedical leader focused on late-stage clinical phase III trials, renowned Wall Street investment firm William Blair upgraded the vaccine manufacturer’s rating from “Market Perform” to “Outperform.” Moderna CEO Stéphane Bancel stated in an interview that, pending regulatory approval, the personalized vaccine called “intismeran autogene” could be approved as early as 2027.

Wall Street reacted with extreme polarization following the announcement: Currently, the highest verifiable new target price comes from Bank of America, where Alec Stranahan upgraded Moderna from “Underperform” to “Neutral” and sharply raised the target price from $40 to $170. He believes intismeran is a “watershed” that could transition Moderna from an infectious disease vaccine company to an oncology platform, unlocking the option value of nine cancer trials and potentially easing long-term R&D investment and cash burn pressures. Piper Sandler maintained an “Overweight” rating, raising its target price from $77 to $167, while Goldman Sachs raised its price target to $120.

If calculated based on the pre-announcement closing price of $62.96, $170 would have represented a potential upside of about 170%. However, Moderna then skyrocketed in a single day by 176.97% to $174.38, already surpassing this highest target price and now potentially facing a 2.5% downside. This partly indicates that the scientific breakthrough has thoroughly reshaped the company’s value, but it also means the market has priced in significant melanoma commercialization and cross-cancer success expectations in a single day. The next real valuation anchor will shift from “will it succeed” to phase III risk ratios, patients’ absolute survival benefits, the likelihood of approval in 2027, and the ability to replicate the results in other solid tumors.

Why is Moderna’s first phase III victory considered a “beacon of hope” for human cancer therapy?

The breakthrough by Moderna and Merck is not merely the success of a typical vaccine but the first clinical validation of personalized neoantigen therapy (INT) in a randomized, double-blind, global phase III trial: INTerpath-001 enrolled 1,137 melanoma patients (stages IIB–IV) whose tumors had been completely resected but who remained at high risk of recurrence. The combination of intismeran autogene and Keytruda reached both the primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS), with no new safety signals identified.

This is the world's first personalized neoantigen therapy to achieve positive phase III results, as well as the first mRNA-based cancer therapy to succeed in a phase III trial, and for the first time, significantly outperformed Keytruda (the standard treatment) in adjuvant therapy for melanoma. For accuracy: previous phase IIb five-year follow-ups showed a 49% reduction in risk of recurrence or death, and a 59% reduction in risk of distant metastasis or death; the specific risk ratio, absolute benefit, and overall survival (OS) data for phase III have yet to be disclosed.

Its underlying technology is not a universal, preventive “cancer vaccine” for everyone, but a treatment platform based on “tumor sequencing—neoantigen prediction—personalized mRNA design—precise immune activation”: Researchers read the unique mutational fingerprint of a patient’s tumor, select up to 34 neoantigens, and encode them into synthetic mRNA. After injection, these antigens are expressed by the patient's cells, training cytotoxic T-cells to recognize cancer cells. Keytruda then removes the PD-1 immune checkpoint inhibition on T-cells. The two therapies together solve the crucial bottlenecks of “accurate tumor recognition” and “sustained attack.”

This breakthrough in cancer treatment by Moderna and Merck, reaching its primary endpoint, is a major boon for high-risk melanoma patients and may open new avenues for other solid tumors such as lung, bladder, kidney, and pancreatic cancer. However, this does not yet mean that humanity has “conquered cancer”—comprehensive phase III data, overall survival benefits, regulatory reviews, as well as verification of the customized vaccine’s production cycle, cost, and ability for large-scale delivery, are still awaited.

From COVID vaccines to tumor immunotherapy: Moderna rewrites mRNA’s valuation trajectory with its first phase III victory

Following the announcement of this trial result—after having previously seen its stock surge due to mRNA vaccines during the COVID-19 pandemic—Moderna’s German-based mRNA rival BioNTech (BNTX.US) also saw its stock rise, as did U.S. vaccine maker Novavax (NVAX.US). Meanwhile, the SPDR S&P Biotech ETF (XBI.US) representing the biotech sector climbed over 4% overall; if sustained, this would mark its best run of daily gains and the strongest monthly price increase since March.

This rally stems from the success of a late-stage clinical trial that evaluated the efficacy of intismeran in combination with Merck’s (MRK) blockbuster drug Keytruda. Compared to Keytruda monotherapy, the combination hit the main endpoint of recurrence-free survival and the secondary endpoint of distant metastasis-free survival.

Merck (MRK.US) and Moderna (MRNA.US) stated that the INTerpath-001 phase III trial enrolled over 1,100 high-risk melanoma patients whose tumors had been completely removed—and highlighted that this was the first late-stage clinical trial in a similar treatment setting to outperform Keytruda.

Senior analyst Myles Minter from William Blair wrote when upgrading Moderna’s stock rating, “The positive results in melanoma adjuvant therapy from the INTerpath-001 study also provide meaningful validation for ongoing studies of intismeran in other cancer types.”

This analyst noted that a total of eight phase II and phase III clinical trials are currently evaluating the efficacy of intismeran in various cancers—including a phase III trial for non-small cell lung cancer, as well as two phase II trials (for renal cell carcinoma and bladder cancer) that have already completed full patient enrollment.

Minter added that results from the phase II adjuvant renal cell carcinoma study—expected by year-end—may be the next major catalyst, and that the study may have registration-supporting potential. He also pointed out that the two companies are advancing intismeran’s development under a profit-sharing agreement, with each holding 50% of the proceeds.

This technology turns part of cancer treatment into a “programmable bioinformatics pipeline”: sequencing the patient’s tumor, using bioinformatics and machine learning to select the new antigens most likely to be recognized by the immune system, and encoding up to 34 antigens into a custom mRNA. The mRNA then trains T-cells to recognize the tumor’s mutational fingerprint, while Keytruda removes the PD-1 immune checkpoint brake, enabling T-cells to continue destroying residual cancer cells.

Therefore, while optimists like Elon Musk stress that “artificial RNA makes disease a software problem,” this view rightly highlights the programmable nature of the platform, but underestimates complex biological constraints such as antigen presentation, HLA variation, tumor microenvironment, and immune evasion. What will truly determine the platform’s value will be its ability to replicate the strong immunogenic response seen in melanoma to non-small cell lung cancer, renal cancer, and bladder cancer: Based on this, Goldman Sachs has set the probability of success for melanoma at 100%, and for non-small cell lung cancer at 85%, estimating respective global peak sales at $4.3 billion and $6.6 billion. However, these are gross sales estimates before accounting for the 50/50 profit split with Merck.